Peptide IndexPeptide Index
Peptide Index
← Home

Reference Repository

Primary citations behind every peptide entry. Includes Phase III RCTs, mechanistic reviews, and observational/research-grade publications. 60 sources.

  1. 1.AbbVie. Lupron Depot Prescribing Information.Find on PubMed
  2. 2.ACOG Practice Bulletin No. 107: Induction of Labor. Obstet Gynecol. 2009;114:386-97.Find on PubMed
  3. 3.Anger JT et al. Pentosan polysulfate sodium for interstitial cystitis. Cochrane Database. 2010.Find on PubMed
  4. 4.Ashmarin IP et al. Semax in the treatment of stroke. Zh Nevrol Psikhiatr. 2005;105:24.Find on PubMed
  5. 5.AstraZeneca. SYMLIN (pramlintide) Prescribing Information.Find on PubMed
  6. 6.Baar MP et al. Targeted apoptosis of senescent cells via a FOXO4-p53 interfering peptide. Cell. 2017;169:132.Read published work
  7. 7.Blanes-Mira C et al. A synthetic hexapeptide (Argireline) inhibits neuronal exocytosis. Int J Cosmet Sci. 2002;24:303.Read published work
  8. 8.Bowers CY. GH releasing peptides — clinical use. J Clin Endocrinol Metab. 1996;81:1577.Read published work
  9. 9.Buse JB et al. Exenatide once weekly vs twice daily (DURATION-1). Lancet. 2008;372:1240.Read published work
  10. 10.Cosman F et al. Romosozumab Treatment in Postmenopausal Osteoporosis (FRAME). N Engl J Med. 2016;375:1532.Read published work
  11. 11.Diamond LE et al. PT-141, a melanocortin agonist for sexual dysfunction. Int J Impot Res. 2004;16:51.Find on PubMed
  12. 12.Dorr RT et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide. Life Sci. 1996;58:1777.Read published work
  13. 13.Eli Lilly. Humalog (insulin lispro) Prescribing Information.Read published work
  14. 14.Falutz J et al. Effects of tesamorelin on visceral fat in HIV-associated lipodystrophy. N Engl J Med. 2007;357:2359.Read published work
  15. 15.Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503.Read published work
  16. 16.Garaci E et al. Thymosin α1: from basic research to clinical use. Expert Opin Biol Ther. 2007;7:1535.Read published work
  17. 17.Garvey WT et al. CagriSema in Adults with Overweight or Obesity (REDEFINE-1). N Engl J Med. 2025.Read published work
  18. 18.Goldspink G. Mechano-Growth Factor: a target for hypertrophy & repair. J Musculoskelet Neuronal Interact. 2005;5:344.Find on PubMed
  19. 19.Goldstein AL et al. Thymosin β4: Therapeutic potential. Expert Opin Biol Ther. 2012;12:37-51.Read published work
  20. 20.Hashimoto Y et al. A rescue factor for Alzheimer's disease: Humanin. Proc Natl Acad Sci. 2001;98:6336.Read published work
  21. 21.Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604). J Clin Endocrinol Metab. 2001;86:5663.Read published work
  22. 22.Imbimbo BP et al. Hexarelin: a novel GH-releasing peptide. J Endocrinol Invest. 1994;17:325.Find on PubMed
  23. 23.Jastreboff AM et al. Tirzepatide for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205.Read published work
  24. 24.Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2. N Engl J Med. 2023;389:514.Read published work
  25. 25.Khavinson VK et al. Epitalon peptide and telomerase activation. Bull Exp Biol Med. 2003;135:590.Read published work
  26. 26.Khavinson VK et al. Peptidergic regulation of aging. Adv Gerontol. 2014;27:257.Find on PubMed
  27. 27.Kingsberg SA et al. Bremelanotide for HSDD: Phase 3 RECONNECT Trials. Obstet Gynecol. 2019;134:899.Read published work
  28. 28.Kozlovskaya MM et al. Selank: anxiolytic and nootropic activity. Eksp Klin Farmakol. 2003;66:31.Find on PubMed
  29. 29.le Roux CW et al. Survodutide for Obesity — Phase 2 RCT. N Engl J Med. 2024;391:719.Read published work
  30. 30.Lee C et al. The mitochondrial-derived peptide MOTS-c regulates insulin sensitivity. Cell Metab. 2015;21:443.Read published work
  31. 31.Lee SJ. Quadrupling muscle mass in mice by targeting myostatin & follistatin. PLoS ONE. 2007;2:e789.Read published work
  32. 32.Leffler DA et al. Larazotide acetate for celiac disease — Phase 2b RCT. Gastroenterology. 2015;148:1311.Read published work
  33. 33.Locatelli V, Torsello A. GHRP-6 review. Curr Pharm Des. 2004;10:2255.Find on PubMed
  34. 34.Luger TA et al. Anti-inflammatory potency of α-MSH/KPV. Ann N Y Acad Sci. 2003;994:133.Read published work
  35. 35.Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375:311.Read published work
  36. 36.Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-44.Read published work
  37. 37.McCoy AT et al. Dihexa, a small molecule HGF mimetic enhances cognition. J Pharmacol Exp Ther. 2013;344:141.Read published work
  38. 38.Miller PD et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures (ACTIVE). JAMA. 2016;316:722.Read published work
  39. 39.Muresanu DF et al. Cerebrolysin in Acute Ischemic Stroke (CARS). Stroke. 2016;47:151.Read published work
  40. 40.Nass R et al. Effects of an oral ghrelin mimetic on body composition. Ann Intern Med. 2008;149:601.Read published work
  41. 41.Neelakantan H et al. Selective NNMT inhibitor (5-Amino-1MQ) reverses diet-induced obesity. Biochem Pharmacol. 2018;147:141.Read published work
  42. 42.Neer RM et al. Effect of parathyroid hormone on fractures and bone mineral density (Fracture Prevention Trial). N Engl J Med. 2001;344:1434.Read published work
  43. 43.Oliynyk S, Oh S. The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance. Biomol Ther. 2012;20:446-56.Read published work
  44. 44.Pickart L, Margolina A. Regenerative & Protective Actions of the GHK-Cu Peptide. Int J Mol Sci. 2018;19:1987.Read published work
  45. 45.Plata-Salaman CR et al. P21 (Cerebrolysin-derived) — neurogenesis review. CNS Drug Rev. 2007.Find on PubMed
  46. 46.Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139:552.Read published work
  47. 47.Rickels MR et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia. Diabetes Care. 2016;39:264.Read published work
  48. 48.Robinson LR et al. Topical palmitoyl pentapeptide (Matrixyl) clinical study. Int J Cosmet Sci. 2005;27:155.Read published work
  49. 49.Sanofi. DDAVP (desmopressin) Prescribing Information.Find on PubMed
  50. 50.Schoenenberger GA. DSIP: a still unresolved riddle. J Neural Transm. 1984;21:367.Find on PubMed
  51. 51.Serono. Geref (sermorelin) Prescribing Information (discontinued 2008).Find on PubMed
  52. 52.Sikiric P et al. BPC 157, A Body Protection Compound: Review. Curr Pharm Des. 2018;24:1990-2001.Read published work
  53. 53.Skorupskaite K et al. Kisspeptin and reproductive function. Hum Reprod Update. 2014;20:485.Read published work
  54. 54.Szeto HH. Cardiolipin-targeted peptide SS-31 (Elamipretide). Br J Pharmacol. 2014;171:2029.Read published work
  55. 55.Teichman SL et al. Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91:799.Read published work
  56. 56.Tomas FM et al. Long-R3-IGF-I promotes nitrogen retention in rats. J Endocrinol. 1993;137:413.Read published work
  57. 57.Vandamme D et al. A comprehensive summary of LL-37. Cell Immunol. 2012;280:22.Read published work
  58. 58.Wharton S et al. Daily Oral Orforglipron for Obesity — Phase 2. N Engl J Med. 2023;389:877.Read published work
  59. 59.Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989.Read published work
  60. 60.Wong F et al. Terlipressin plus Albumin for Hepatorenal Syndrome Type 1 (CONFIRM). N Engl J Med. 2021;384:818.Read published work
Sign in to save favorites & stacks

Educational reference only. Not medical advice. Consult a qualified clinician before starting any peptide protocol.

Non-FDA-approved peptides are for research use only. Not for human or animal consumption.